Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Inozyme Pharma (INZY) Stock Price & Analysis
288 Followers
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $7.80
Previous Close$4.82
Volume276.00K
Average Volume (3M)639.22K
Market Cap
$298.14M
Enterprise Value$156.15M
Total Cash (Recent Filing)$188.59M
Total Debt (Recent Filing)$46.59M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 07, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding61,855,509
10 Day Avg. Volume321,142
30 Day Avg. Volume639,220
Standard Deviation0.32
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.12
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$16.25Price Target Upside237.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Inozyme Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive topline data from Phase 1/2 trial of adults with ENPP1 Deficiency was announced, reflecting INZ-701's promise and paving the way for further clinical development.
Drug Development ProgressINZ-701 has orphan drug designation from the EMA and the FDA, and also has FDA fast track and rare pediatric disease designations, signifying its potential to address unmet medical needs.
Market OpportunityAnalyst recommends a Buy rating with a $14 price objective for Inozyme, highlighting the significant market opportunity given no approved therapies and data supporting INZ-701's potential clinical benefit.
Bears Say
Earnings MissInozyme reported EPS of ($0.38), compared to the estimate of ($0.35).
Financial Performance DowngradeFor FY24, the EPS estimate has been decreased to ($1.64) from ($1.53).
Regulatory UncertaintySome Questions Remain on ABCC6 and Calciphylaxis, creating uncertainty on the program's endpoints and regulatory approval.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $2.69 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is Aug 07, 2024 which is in 66 days.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on May 07, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.36 by -$0.02.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.39.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 61,855,510 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.36. Following the earnings report the stock price went down -5.738%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Woodline Partners LP. It holds Inozyme Pharma’s shares valued at 7M.
---
Inozyme Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.25 (237.14% Upside)
$16.25 (237.14% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 589.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.53%
12-Months-Change
Fundamentals
Return on Equity
-69.41%
Trailing 12-Months
Asset Growth
24.79%
Trailing 12-Months
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Month Forecast
Average Price Target
$16.25
▲(237.14% Upside)
Technical Analysis
Best Analysts Covering INZY
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+24.88%
reiterated a buy rating 26 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.88% per trade.
---